Development of new biotech drugs at reduced costs - Fiotec

One of the main bottlenecks in the technological development chain for biotech drugs is the availability of installations equipped for Good Manufacturing Practices (GMP) for the production of batches for use in clinical trials.

The finalization of the prototypes plant of the Integrated Center for Prototypes, Biological Drugs, and Diagnostic Reagents (CIPBR) at Bio-Manguinhos is one of the largest investments in innovation and technological development in Brazil, and that will lead to scale-up of products developed on the laboratory bench and for manufacturing batches for clinical studies, in addition to the expansion of technological capability.

The prototypes plant will be multipurpose, since it will have the flexibility to process a variety of biotechnological products. The presence of expertise in production and technological development in an appropriate space will contribute to the process of technological innovation.